Adriamycin-vitamin E combination therapy for treatment of prostate adenocarcinoma in the Nb rat model.
Adriamycin used in combination with vitamin E (Tocopherol) was evaluated in the treatment of Nb rat prostate adenocarcinoma. Vitamin E has been shown to enhance the growth-inhibitory effects of adriamycin on human prostatic carcinoma cells in vitro. The adriamycin-vitamin E treatment groups had the lowest average final tumor volume, but the mortality rate was 57% (17/30). These results suggest that vitamin E may play a role in enhancing the cytotoxic effects of adriamycin, but may not have any protective effect on normal cells as previously suggested through in vitro methods.
Nesbitt
J A
JA
Department of Surgery, College of Medicine, Ohio State University, Columbus 43210.
Smith
J
J
McDowell
G
G
Drago
J R
JR
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000818:Animals; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D051381:Rats; D014810:Vitamin E / Q000008:administration & dosage / Q000627:therapeutic use*
D014810:Vitamin E; D004317:Doxorubicin